Videos

Expert Perspectives on Quadruplet Therapy Regimens for Patients With Multiple Myeloma

Experts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

The panel shares some personal experiences with treating patients with multiple myeloma with a quadruplet therapy regimen.

A panel of 4 experts on multiple myeloma seated at a long table

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Talquetamab for Patients With Relapsed/Refractory MM

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Debate on Efficacy and Patient Selection With Ixa-Pom-Dex in Relapsed/Refractory MM

Expert insight into the later-line efficacy and tolerability of olverembatinib, a third generation TKI, in ponatinib-resistant, refractory chronic myeloid leukemia populations.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Evaluating Ponatinib and Asciminib as 3L Therapy in CML

Leading experts discuss the potential benefits and challenges of using ixazomib pomalidomide-dexamethasone as a treatment option for relapsed myeloma patients, considering factors like efficacy, overall survival, and patient demographics.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Ixa-Pom-Dex as Second-Line Therapy in Relapsed/Refractory MM: Alliance A061202

Considerations for selecting between ponatinib and asciminib as third-line therapies for CML based on factors such as disease burden, mutations, and patient tolerability.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Patient Scenario 1: 65-Year-old Woman with R/R Follicular Lymphoma

Rahul Banerjee, MD, FACP, discusses the Alliance A061202 trial, presenting the potential benefits and red flags of using ixazomib-pomalidomide-dexamethasone combination in relapsed myeloma treatment.

Brian T. Hill, MD, PhD;Jennifer L. Garson, PA-C;Muhamad Alhaj Moustafa, MD, MS;Tycel Phillips, MD

September 30th 2023

A panel of experts present that case of a 65-year-old woman with follicular lymphoma and discuss potential approaches for treatment in the relapsed or refractory setting.

The Evolution of the Treatment Landscape for Follicular Lymphoma

Brian T. Hill, MD, PhD;Jennifer L. Garson, PA-C;Muhamad Alhaj Moustafa, MD, MS;Tycel Phillips, MD

September 30th 2023

Expert oncologists discuss the evolving treatment landscape for follicular lymphoma and highlight key advances that have contributed to improved treatment options.

Currently Available Treatment Options for Patients With CLL

Asher A. Chanan-Khan, MBBS, MD;Ricardo Parrondo, MD;Pooja Advani, MBBS, MD

Clinical Case Scenario: A 55-Year-Old Patient With Chronic Lymphocytic Leukemia (CLL)

Mayo Clinic experts note that targeted therapies for chronic lymphocytic leukemia are generally superior to chemoimmunotherapy, with treatment choices tailored to patient comorbidities and preferences, and noting that real-world data mostly aligns with clinical trials.

Asher A. Chanan-Khan, MBBS, MD;Ricardo Parrondo, MD;Pooja Advani, MBBS, MD

Patient Scenario: A 66-Year-Old Male With BRAF-Mutant mCRC

In a virtual discussion hosted by Asher A. Chanan-Khan, MD, MBBS, experts from Mayo Clinic discuss treatment strategies for chronic lymphocytic leukemia, including the role of cardio-oncology and various therapeutic approaches.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

Approaches for Treatment Sequencing in Patients With HER2+ mCRC

Daniel Walden, MD, presents the scenario of a 66-year-old man diagnosed with BRAF V600E-mutant metastatic colorectal cancer to the expert panel for discussion.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

Recent Updates for Biomarker Testing in Breast Cancer

In a detailed conversation, Tanios Bekaii-Saab, MD, Daniel Ahn, DO, and Christina Wu, MB, BCh, MD, discuss various scenarios for treating HER2+ metastatic colorectal cancer, focusing on patient profiling, testing methods, and different sequencing strategies including the use of trastuzumab.

Sara M. Tolaney, MD, MPH

September 28th 2023

Expert insights on biomarker testing in breast cancer, with a focus on key markers associated with specific subtypes.

The Overall Breast Cancer Landscape

Sara M. Tolaney, MD, MPH

September 28th 2023

Sara M. Tolaney, MD, MPH, an expert breast oncologist, reviews the overall treatment landscape for breast cancer.

Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

MM: Influence of CAR T-Cell Therapy on Clinical Care

Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Toxicity Management in Patients With Multiple Myeloma

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Choosing Between Bispecific or CAR T-Cell Therapy for Patients With Multiple Myeloma

Experts explain strategies for toxicity management in patients receiving treatment for multiple myeloma, including monitoring risk of CRS.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

AI May Assist in Prostate Cancer Diagnosis, Risk Stratification, and Treatment

Shared insight on the factors to consider when choosing between a bispecific therapy and CAR T-cell therapy for a patient with multiple myeloma.

Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Imaging, Patient Demographics May Inform AI Learning in Prostate Cancer

Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Artificial intelligence may help detect tumors both within the prostate and that have spread to areas outside of the prostate, according to Wayne G. Brisbane, MD.

Asciminib in CML Treatment: Efficacy and Responses Shown in the ASCEMBL Study

Artificial intelligence may help detect tumors both within the prostate and that have spread to areas outside of the prostate, according to Wayne G. Brisbane, MD.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Exploring the Role of Ixazomib in Relapsed/Refractory Multiple Myeloma

A review of promising results from the ASCEMBL study, highlighting asciminib's superior efficacy, well-tolerated profile, and potential impact on chronic myeloid leukemia treatment options.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Managing Cardiovascular Risks in CML Treatment

Key insights on real-world applications of the REMIX study, which evaluated real-world effectiveness and tolerability of the ixazomib-based regimen in relapsed/refractory multiple myeloma.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

REMIX Study: Ixa-Len-Dex for Relapsed/Refractory Myeloma

A panel of experts discusses the challenges and considerations surrounding cardiovascular risks associated with ponatinib treatment for chronic myeloid leukemia, emphasizing the need for multidisciplinary collaboration and individualized treatment strategies.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Selecting Patients Best Suited for AI Prostate Cancer Detection

Outcomes of the REMIX study investigating the effectiveness and tolerability of ixa-len-dex in real-world relapsed/refractory myeloma patients, exploring progression-free survival, overall response rate, and safety.

An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.

AI May Help With MRI Interpretation During Prostate Cancer Detection

September 25th 2023

An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.

Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.